A convenient pathway to control drug release from hybrid assembly nanoparticles of several kinds of copolymers was investigated in this paper. Three kinds of biodegradable amphiphilic copolymers, poly(ethylene glycol)-block-poly(L-lactic acid), poly(ethylene glycol)-block-poly(D,L-lactic acid) and poly(ethylene glycol)-block-polycaprolactone-poly(ethylene glycol) were used to assemble into hybrid assembly nanoparticles as carriers of paclitaxel. The results show that small spherical hybrid assembly nanoparticles (diameter < 100 nm) with good paclitaxel loading ability and entrapping efficiency were obtained simply through hybrid assembling of different copolymers. The in vitro release studies indicate that paclitaxel release rate can be controlled easily by varying the ratio of the hybrid copolymers. The release control mechanism is assigned to the crystallization adjustment of the cores of hybrid assembly nanoparticles which provide a convenient approach to control drug release for drug-loaded nanoparticles.
INTRODUCTION
Many drugs are toxic or hold serious side effects. Such problems have spurred the development of various drug delivery systems (DDS), such as polymer micelles, nanoparticles (NPs), liposomes, and polymer-drug prodrug systems. [1] [2] [3] [4] [5] [6] [7] NPs have overwhelming advantages for cancer chemotherapy. [8] [9] [10] [11] [12] Taking hydrophobic character of drugs into account, NPs formed from biodegradable amphiphilic block copolymers offer promising strategies for hydrophobic delivery. 1 2 Amphiphilic block copolymers, which hold self-assembly ability in aqueous environment, become great choice for NPs. The hydrophobic parts of the copolymer can form the core of the NPs, while the hydrophilic blocks form the outer shell. The hydrophobic core applies a microenvironment for hydrophobic drugs, while the hydrophilic outer shell serves as a stabilizing interface between the core and external medium. Of the various available amphiphilic copolymers for anticancer drugs, biodegradable polyether-polyester, such as poly(ethylene glycol)-block-poly(L-lactic acid) (PELLA), poly(ethylene glycol)-block-poly(D,L-lactic acid) (PEDLLA) and poly(ethylene glycol)-block-polycaprolactone-block-poly-(ethylene glycol) (PECL), were well investigated. 2 13-17 It has been certificated that the polyether-polyester NPs * Author to whom correspondence should be addressed.
can increase the therapeutic benefit meanwhile minimize the side effects of the loaded drug. With PEG layer, they can evade the recognition and subsequent uptake by RES, and thus prolong the drug circulation time in the blood compartment, which makes it possible for passive accumulation in cancer tissues. 18 19 Despite their great promising as drug carriers for targeted delivery, NPs currently made for cancer are still have some drawbacks in drug release aspects which greatly confine their more effective clinical application. NPs tend to immediately release a large fraction of the carried drug into the bloodstream after intravenous administration. The initial burst release may be up to 40% of the drug content. After the initial burst release, the drug release from the NPs became very slow. [20] [21] [22] As a result, the drug concentration in cancer cells is still lower which thus causes non-targeted drug release and low drug efficiency.
Release of the drugs from NPs depends upon the nature of the delivery system. In the case of matrix device, drug is uniformly distributed/dissolved in the matrix and the release occurs by diffusion or erosion of the matrix. If the diffusion of the drug is faster than matrix degradation, the mechanism of drug release occurs mainly by diffusion, otherwise it depends upon degradation. 23 24 The initial burst release is attributed to the more fraction of the drug, which is adsorbed or weakly bound to the large surface area of the NPs, than to the drug incorporated in NPs.
An exponential delayed release rate is observed probably due to the drug diffusion from the matrix. [24] [25] [26] [27] [28] It has been known that, for the biodegradable polyether-polyester carrier, the drug release rate depends on the ratio of polyester segment and PEG segment, the molecular weight, the interaction between the drug and the polymer, and characters especially the crystallization of the polyester segments. Our previous studies showed that the drug release rate of paclitaxel-loaded PLA-b-PEG NPs obviously decreased as the drug loading content increased, and it increased with increasing the content of hydrophilic segments or decreasing molecular weight of the copolymer. [29] [30] [31] The similar phenomena were also observed by other researchers. Avgoustakis et al. found that an increase in the content of mPEG caused an increase in the release rate of insulin from PLGA-mPEG NPs. 32 Until now, the works about the drug delivery and release of PEGylated NPs were limited on the point of pure copolymers, drug release rate mostly controlled by molecular weight and ratio of hydrophilic chain and hydrophobic chain, [33] [34] [35] which means different molecular weight carriers with different ratios of hydrophilic chain and hydrophobic chain have to be synthesized to meet the requirement of different drug release rates. This paper aims to provide a convenient method to adjust the drug release by hybrid assembly nanoparticles (HNPs) using two or three kinds of PEGylated copolymers. Paclitaxel was adopted as drug model, because it has great effective for various cancers especially ovarian and breast cancer but continues hold serious side effects including dyspnea, flushing, rash and urticaria. 2 The release of paclitaxel from HNPs and the crystal characters of HNPs were investigated in this paper. 
MATERIALS AND METHODS

Instruments
Differential scanning calorimetry (DSC) measurements were carried out on Perkin-Elmer DSC (Shimadzu, Tokyo, Japan). All DSC thermograms were recorded in the range of −50 C to 200 C under a liquid nitrogen purge and with a heating rate of 5 C/min in nitrogen.
Wide angle X-ray diffraction (WAXD) patterns were recorded with graphite-filtered Cu K radiation produced with a Rigaku Denki Model D/MAX-RA Diffractometer (Rigaka, Tokyo, Japan). Pseudo-Voigt 2 peak function from Origin 7.0 was used to deconvolute the WAXD diffractograms into peaks and halos corresponding to the crystalline and amorphous regions, respectively. 36 The crystalline degree of NPs and HNPs was calculated according to the areas of the crystal peaks and the amorphous region, as formula (1):
Where X c is crystalline degree (%); S c is the area of crystallized region which is sum of areas of crystal peaks and S a is the area of amorphous region integrated from WAXD spectra.
The size and distribution of NPs and HNPs were determined on a BI 9000 AL Photon Correlation Spectroscope (Brookhawen, New York, USA), with Ar ionic laser ( = 514 5 nm, measure angle = 90 , temperature = 25 C).
The morphological evaluation of the HNPs (NPs) was performed by transmission electron microscopy (TEM). Frozen dried powder of HNPs (NPs) was redispersed in ether as sample solution. Specimens for TEM were prepared by dropping the sample solution into a copper grid. The grid was held horizontally for 20 s to allow the molecular aggregates to settle. A drop of phosphotungstic acid was added to give a negative stain. After specimens were air dried, TEM images were taken using a Philips EM400ST transmission electron microscope (Eindhoven, Netherland) at an accelerating voltage of 80 kV.
The amount of paclitaxel was estimated by high performance liquids chromatogram (HPLC, Agillent1100, USA) using Hypersil ® ODS-2 (250 × 4 6 mm) C18 column. The paclitaxel was detected at 254 nm with a mobile phase of acetonitrile and water (65:35, v/v). The measurements were performed at the temperature of 30 C with a flow rate of 1.0 mL/min.
Preparation of PEGylated Copolymers
Three PEGylated copolymers, PELLA, PEDLLA and PECL, were prepared by the methods reported before. [29] [30] [31] In brief, PELLA and PEDLLA were prepared by the melt polycondensation of mPEG and LLA or DLLA with the mixture of stannous chloride and p-toluenesulfonic acid (molar ratio 1:1) as catalyst. PECL triblock copolymer was prepared by reacting PEG, PCL and TDI in solvent. 
Preparation of Paclitaxel Loaded NPs and HNPs
NPs of PELLA (NPs PELLA ) were prepared by the following method. 29 Briefly, 100 mg copolymer dissolved in 3 mL dichloromethane (DCM), and then certain amount of paclitaxel was dissolved into the copolymer solution. Redistilled water (10 mL) was dropwise added to the copolymer-drug solution stirring with a magnetic stir bar and the mixture solution formed discrete droplets in aqueous continuous phase. Agitation of the system was continued until DCM partitioned into the aqueous phase and removed by evaporation.
NPs of PEDLLA (NPs PEDLLA ), NPs of PECL (NPs PECL ) and HNPs were prepared by the method as described before. 30 31 Paclitaxel and the two copolymers were dissolved in acetonitrile followed by evaporation of the solvent under a stream of nitrogen at 60 C for 2 h to obtain a solid paclitaxel: copolymer matrix. Then the solid paclitaxel: copolymer matrix was preheated in a warm water bath at 60 C to obtain a transparent gel-like matrix. This was followed by the addition of 60 C water or phosphate buffered saline (PBS, pH = 7 4) and stirring to obtain a clear nanoparticle solution.
Above processes result in a hardened inner core of NPs and HNPs that contains paclitaxel. Then, the dispersion was centrifuged to eliminate the unloaded paclitaxel crystal and the aggregated particles. The supernatant was frozen and lyophilized by freeze dryer system to obtain NPs or HNPs powder. The molecular weights of amphiphilic copolymers were calculated by integrations in NMR spectra.
Drug Loading Content Measurements
Paclitaxel-loaded NPs or HNPs were dissolved in acetonitrile (5 mL; a common solvent for both polymer and paclitaxel) and injected into HPLC. After standard curve of paclitaxel was calibrated, the drug loading content (LC % w/w) and drug entrapment efficiency (EE %) were defined as the weight ratio of paclitaxel in HNPs (NPs) to weight of HNPs (NPs), as presented by formula (2) and (3), respectively.
LC % = weight of paclitaxel in HNPs (NPs) weight of HNPs (NPs) × 100%
EE % = weight of paclitaxel in HNPs (NPs) weight of paclitaxel fed initially × 100% (3)
In Vitro Release of Paclitaxel from HNPs and NPs
HNPs (NPs) were well dispersed in PBS (pH 7.4, 2 mL), and then placed in a dialysis bag which was immersed in a large vial containing warmed PBS (28 mL, 37 C), stirring with a magnetic stir bar. At the appropriate time intervals, a 20 mL aliquot of PBS outside the dialysis bag in the large vial was removed out to measure the amount of paclitaxel released from HNPs (NPs). After the removal of each 20 mL aliquot, a 20 mL aliquot of fresh PBS was supplemented. The amount of paclitaxel in the release medium was determined by HPLC. The accumulated release was calculated as following formula (4) .
Where E r is the accumulated release (%); V e is the sampling volume (20 mL); V 0 is the initial volume, 30 mL; C i , C n : paclitaxel concentration ( g/mL); I and n are the sampling times; and m drug is the mass of paclitaxel in HNPs (NPs) ( g). Figure 1 shows the TEM images of HNPs with different copolymer composition. These images confirm that the HNPs are spherical morphology with the core/shell structure and discrete particles in aqueous media. The drug loading properties of the NPs of single copolymer PEDLLA, PELLA, PECL and different HNPs were listed in Table II. The particle size distributions of the NPs (HNPs) were shown in Figures 2 and 3 . It can be seen that all though the hybrid assembly of two copolymers leads to a slightly decrease in EE % compared with the NPs of single copolymer, all the HNPs present good (c) Fig. 1 . TEM images of HNPs; (a) NPs PEDLLA with 9.7% w/w paclitaxel; (b) HNPs PELLA/PEDLLA=1/5 with 9.6% w/w paclitaxel; (c) HNPs PECL/PEDLLA=1/5 with 9.3% w/w paclitaxel. Frozen dried powder of HNPs (NPs) was redispersed in ether as sample solution. Specimens for TEM were prepared by dropping the sample solution into a copper grid. A drop of phosphotungstic acid was added to give a negative stain. After specimens were air dried, TEM images were taken using a Philips EM400ST transmission electron microscope (Eindhoven, Netherland) at an accelerating voltage of 80 kV.
RESULTS AND DISCUSSION
Characters of NPs and HNPs
paclitaxel entrapment efficiency which is near to 90%. The HNPs take small average diameters (<100 nm) but bigger than that of NPs PEDLLA . Upon increasing the content of PELLA or PECL, the sizes of the HNPs increase slightly but the polydispersity of the size distribution are similar. It has been reported that PLLA and PCL are semicrystalline polymers, and PDLLA is amorphous polymer, 37 38 therefore the crystal core formed by PELLA or PECL leads to bigger NPs than those formed by PEDLLA when the same amount of paclitaxel is loaded. Similarly, the hybrid assembly of PLLA or PECL with PDLLA induces bigger HNPs and the increase in particle size with increasing PELLA or PECL. The slightly decrease in EE % might 
c Polydispersity of size distribution of HNPs (NPs). Here NPs mean nanoparticles and HNPs mean hybrid assembly nanoparticles. LC % means percentage of drug loading content. EE % means percentage of drug entrapment efficiency. Average diameter of particles and polydispersity of size distribution of HNPs (NPs) were detected by on a BI 9000 AL Photon Correlation Spectroscope, with Ar ionic laser ( = 514 5 nm, measure angle = 90 , temperature = 25 C).
due to the phase change of the cores as shown in the crystal studies below. When PEDLLA or PECL co-assembles into HNPs with PEDLLA, the expected results are seen clearly that the release rate of paclitaxel from the HNPs is well controlled by varying the ratio of PEDLLA and PELLA (or PECL); and no burst release appears. The release rate of paclitaxel from HNPs decreases with increasing the content of PELLA or PECL and locates between those of the two single copolymer NPs. HNPs present excellent ability in controlling drug release, i.e., a stable drug release rate reaches after 5 h which is similar to that of the pure copolymer NPs. These results indicate that hybrid assembly of different copolymers is a convenient pathway to obtain the expected drug release rate.
In Vitro Release of Paclitaxel from HNPs and NPs
To explain the difference controlled release rate of paclitaxel in NPs PEDLLA and NPs PELLA , the paclitaxel release . This result indicates that the effect of particle size on drug release is not the dominative parameter, which is further confirmed by Figure 4 . The particle sizes of HNPs PELLA/PEDLLA=5/5 , HNPs PELLA/PEDLLA=4/5 and NPs PELLA are similar, but NPs PELLA presents lower release rate than the two others. The study result of PEG-PCL-PEG NPs with similar size also improved above opinion (Date can be seen in the surporting information). Therefore, the crystallization of the core of the NPs was thought as the main reason to control the release.
Crystallization of Copolymer HNPs and NPs
The phase structure of the hydrophobic cores of the HNPs was supposed to dominate the mechanism of HNPs in controlled drug release. Therefore, the crystallization characters of HNPs were studied. PDLLA is an amorphous polymer, but PLLA and PCL are crystalline polymers. In WAXD spectra, PCL shows pronounced peaks at 2 = 22 and 24 , PLLA at 2 = 17 and 19 . 39 40 The WAXD spectra of NPs and HNPs are shown in Figures 6 and 7 . A strong characteristic peaks at 2 = 19 and a weak peak at 2 = 24 occur in the WAXD curve of NPs PEDLLA , which are assigned to the crystal of PEG segments. For NPs PELLA in Figure 6 , three characteristic peaks can be seen respectively at 2 = 17 (b), 19 (a) and 24 (c), among which Peak b is the diagnostic peak of PLLA segments and the others are the corporate results of PEG segments and Similar results were observed for HNPs assembled by PEDLLA and PECL as shown in Figure 7 . The peak at the site of b is the diagnostic peak of PCL segments, the Here NPs mean nanoparticles and HNPs mean hybrid assembly nanoparticles. The crystalline degree of NPs and HNPs was the quotient of the total crystal peak area and the sum of the crystal and amorphous area in WAXD spectra. Pseudo-Voigt 2 peak function from Origin 7.0 was used to deconvolute the WAXD diffractograms into peaks and halos corresponding to the crystalline and amorphous regions, respectively. Source: Reprinted with permission from [36] The crystalline degrees of NPs and HNPs are listed in Table III . The crystalline degree of HNPs increases with increasing the content of PELLA or PECL, which is mainly due to the introduction of PLLA or PCL crystalline segments into the core of HNPs. The WAXD spectra indicate that the phase structures of the HNPs also take the hybrid state, i.e., the coexistence of crystal phase of PLLA or PCL and amorphous phase of PDLLA in the core of HNPs. Therefore, controlled release of paclitaxel at different rate can be realized by HNPs. Figures 8 and 9 are the DSC thermograms of different HNPs. As shown in Figure 8 , only one crystalline peak is observed for all the HNPs, which moves to higher temperature with increasing the amount of PELLA or PECL. The crystalline peaks of PEDLLA and PELLA present at about 38 C and 44 C respectively. As to the HNPs, the crystalline peaks of HNP PELLA/PEDLLA=1/5 , HNPs PELLA/PEDLLA=4/5 and HNPs PELLA/PEDLLA=5/5 are at 38, 39, and 40 C respectively, which are more and more close to the crystalline peak of PELLA. The same phenomena also happen to the HNPs systems of PEDLLA and PECL. It also can be seen that the NPs Mixture PELLA/PEDLLA=4/5 has a wider melting peak which tends to higher temperature than that of HNPs PELLA/PEDLLA=4/5 , and the similar difference can be seen for NPs Mixture PECL/PEDLLA=4/5 and HNPs PECL/PEDLLA=4/5 in Figure 9 . These DSC results just correspond with those of WAXD above and further indicate the hybrid structure of HNPs but not the mixture of two copolymer NPs. When 9.4% w/w paclitaxel is entrapped into the HNPs PELLA/PEDLLA=5/5 , labeled as HNPs PELLA/PEDLLA=5/5 (p), the crystal melting point of the HNPs hardly changes (shown in Fig. 8 ). The same result is also observed in Figure 9 for HNPs PECL/PEDLLA=5/5 . So it can be thought that paclitaxel doesn't affect the crystal behavior of PLLA or PCL segments upon forming the core.
CONCLUSIONS
In this study, three kinds of amphiphilic polyesterpolyether block copolymers, PEDLLA, PELLA and PECL were synthesized and HNPs of PEDLLA with PELLA or PECL were prepared successfully. The prepared HNPs present efficient carriers of paclitaxel. They show a spherical morphology with inner core and outer shell. Any initial burst release is not observed in the release pattern of all the HNPs with entrapped paclitaxel. The drug-releasing rate decreases with increasing the content of PELLA or PECL in the HNPs and is between the NPs assembled by single copolymer of PDLLA, PELLA or PECL. WAXD and DSC results indicate that there is coexistence of crystal phase of PLLA or PCL segments and amorphous phase of PDLLA in the core of HNPs, which realizes the controlled release of paclitaxel at designed rate just by adjusting the ratio of PEDLLA and PELLA or PECL. 
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